← All articles
GuidelinePediatrics / American Academy of Pediatrics

Therapeutic Hypothermia for Neonatal Hypoxic-Ischemic Encephalopathy: Clinical Report

First online Jan 26, 2026On EM Weekly Oct 30, 2026Discovered Oct 30, 2026AI-generated Not yet human-reviewed

Summary

This AAP clinical report updates neonatal HIE care. The primary abstract supports cooling eligible infants born at ≥36 weeks within 6 hours for 72 hours, with neuromonitoring, neuroimaging and developmental follow-up.

The retrieved official society summary clarifies selected later-presenting and younger infants and emphasizes coordinated recognition and transfer. This record covers that summary, rather than a full guideline appraisal.

Why it matters

An ED encountering a newborn with suspected HIE should urgently contact a cooling center. Presentation beyond 6 hours should prompt specialist assessment rather than automatic dismissal of possible eligibility.

Study at a glance

Design
Guideline
Population
Newborns with suspected moderate-to-severe hypoxic-ischemic encephalopathy.
Sample size
Not applicable
Intervention
Specialist-directed therapeutic hypothermia and coordinated transfer.
Comparator
Clinical-report recommendations; no new randomized comparison.
Primary endpoint
Prevention of death or moderate-to-severe neurodevelopmental impairment.

Key recommendations

  • Standard approach: initiate within 6 hours, target 33.5°C and continue 72 hours.
  • At 35 0/7–35 6/7 weeks, treatment may be considered after family discussion; below 35 weeks it is not recommended.
  • At 6–24 hours, selected moderate-to-severe HIE cases may be considered after discussing potentially small benefits and risks.
  • Mild HIE: evidence is insufficient. Avoid hyperthermia even when cooling is unsuitable.
  • Transport cooling requires strict protocols. Continuous neuromonitoring and access to pediatric neurology are emphasized.

Limitations

The complete report was not retrieved: its page presented CAPTCHA. Detailed eligibility scoring, exclusion criteria, adverse-event estimates and underlying trials remain unreviewed; use the receiving center’s protocol.

Recommendation strength

AAP recommendations; formal GRADE certainty was not established from reviewed material.

Read the primary source

Full text: Official society summary available.

Original source

DOI: 10.1542/peds.2025-073627

PMID: 41581784

Source retrieved Oct 30, 2026. Official AAP News summary retrieved in full: https://publications.aap.org/aapnews/news/34085/AAP-report-provides-update-on-therapeutic . Primary publisher indexed abstract/date and PubMed identifiers corroborated. DOI-specific correction/retraction search found no separate notice; full-report evidence and safety appraisal remains queued.

Corrections & review history

No corrections recorded. Human review: not yet human-reviewed.